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ABSTRACT
Introduction: The use of dipeptidyl peptidase-4
inhibitors in combination with metformin is
increasing in Japanese patients with type 2
diabetes mellitus (T2DM), but no single-pill
combination (SPC) is currently available in
Japan. The objective of this study was to assess
the efficacy and safety of vildagliptin/
metformin SPC in Japanese patients with
T2DM inadequately controlled with
vildagliptin monotherapy.
Methods: This was a 14-week, randomized,
double-blind, parallel-group, placebo-
controlled trial. 171 patients with T2DM
inadequately controlled [HbA1c (glycosylated
hemoglobin) 7.0–10.0%] with vildagliptin
50 mg twice daily (bid) were randomized (2:1)
to receive either a vildagliptin/metformin SPC
(n = 115) or matching vildagliptin/placebo SPC
(n = 56).
Results: Baseline demographics and
background characteristics were generally
comparable between the treatment groups.
The change in HbA1c [mean ± standard error
(SE)] was -0.8 ± 0.1% in the vildagliptin/
metformin SPC (baseline HbA1c, 7.9 ± 0.1%)
group and 0.1 ± 0.1% in the
vildagliptin/placebo SPC (baseline HbA1c,
8.0 ± 0.1%) group, with a between-treatment
difference of -1.0 ± 0.1% (P\0.001) in favor of
the vildagliptin/metformin SPC group. The
proportion of patients achieving target
HbA1c\7.0% was significantly higher with
vildagliptin/metformin SPC compared with
vildagliptin/placebo SPC (45.8% vs. 13.5%,
P\0.001). The overall incidences of adverse
events (AEs) were 43.5% in the vildagliptin/
metformin SPC and 67.9% in the
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vildagliptin/placebo SPC group. The incidences
of serious AEs were low in both the treatment
groups (0.9% vs. 3.6%, respectively). Body
weight remained constant throughout the
study in both the treatment groups. There
were no deaths or hypoglycemic events during
the study.
Conclusions: Switching Japanese patients with
T2DM requiring treatment intensification, from
vildagliptin monotherapy to a vildagliptin/
metformin SPC (50/250 or 50/500 mg) was
efficacious and safe, eliciting significant
reduction in HbA1c without increased risk of
hypoglycemia and weight gain.
Keywords: Dipeptidyl peptidase-4 inhibitor;
Metformin; Single-pill combination; Type 2
diabetes mellitus; Vildagliptin
INTRODUCTION
The worldwide prevalence of type 2 diabetes
mellitus (T2DM) continues to rise dramatically,
with Asian countries contributing more than
half of the world’s diabetic population [1, 2].
Currently, 7.2 million individuals aged between
20 and 79 years are affected by T2DM in Japan
[1]. T2DM clinical practice guidelines by the
American Diabetes Association [3] and
International Diabetes Federation [4] suggest
starting treatment with metformin unless
contraindicated, followed by the addition of
other oral antidiabetic drugs (OADs) if patients
fail to achieve glycosylated hemoglobin
(HbA1c) goal \7.0%. The Japan Diabetes
Society (JDS) suggests starting
pharmacotherapy with any OAD depending
on the physiological status of the patient after
diet and exercise failure [5]. Most of the
Japanese patients with T2DM have a tendency
to a low body mass index (BMI); and as insulin
secretion deficiency plays a predominant role in
disease pathology [6], insulin secretagogues are
the preferred first-line treatment option in
Japan. Recently, Japanese patients with T2DM
are being increasingly treated with dipeptidyl
peptidase-4 (DPP-4) inhibitors (e.g.,
vildagliptin) [7], which increase insulin
secretion from b-cells in a glucose-dependent
manner [8]. Moreover, the progressive nature of
the disease warrants treatment intensification
with other antidiabetic agents having
complementary mechanism of action to
maintain glycemic control over long term [5].
The mechanistic synergy between
vildagliptin and metformin [8, 9], and the
efficacy and safety of vildagliptin added to
metformin in Japanese patients with T2DM
inadequately controlled with metformin
monotherapy has already been demonstrated
[10]. However, the benefit of switching patients,
who are treated with vildagliptin and require
additional treatment, to vildagliptin and
metformin has not been established. So far, no
DPP-4 inhibitor/metformin single-pill
combination (SPC) is available in Japan. Such
a SPC has the additional benefit of a reduced pill
burden, and potentially better compliance [11].
Moreover, the efficacy of low-dose metformin
[250 mg twice daily (bid)] has not been studied
previously in a randomized trial setting in
Japanese patients with T2DM. Accordingly, the
current study was aimed to assess the efficacy
and safety of vildagliptin/metformin SPC at
doses of 50/250 and 50/500 mg in Japanese
patients with T2DM inadequately controlled
with diet, exercise and vildagliptin
monotherapy.
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MATERIALS AND METHODS
Study Design
This 14-week, multicenter, double-blind,
parallel-group, placebo-controlled, randomized
study was conducted across 30 centers in Japan
from May 2013 to February 2014. Patients with
T2DM inadequately controlled (HbA1c
7.0–10.0%) with diet, exercise and vildagliptin
monotherapy were eligible for inclusion.
Following the screening visit (visit 1), eligible
patients on vildagliptin 50 mg bid
monotherapy for at least 10 weeks proceeded
directly to randomization (baseline, visit 2).
Whereas patients taking other OADs were
switched to vildagliptin 50 mg bid and were
asked to complete a 12-week run-in period (visit
101) before randomization (Fig. 1).
Eligible patients were randomized (2:1) to
receive either vildagliptin/metformin SPC
(hereafter called the vilda/met group) or
vildagliptin/placebo SPC (hereafter called the
vilda/placebo group). In the vilda/met
treatment group, patients were randomized
(1:1) to receive either vilda/met 50/250 or
50/500 mg bid (Fig. 1). In the vilda/met group,
all patients started double-blind treatment with
vilda/met 50/250 mg bid, and patients
randomized to the subgroup vilda/met
50/500 mg bid were up-titrated after 2 weeks.
Efficacy and safety were assessed at baseline and
at weeks 2, 6, 10, and 14. No rescue medication
was allowed, and patients with unsatisfactory
therapeutic effect [fasting plasma glucose
(FPG) C15.0 mmol/L] were discontinued from
the study.
Study Population
The study included patients with T2DM
aged C20 to\75 years, BMI C20 to B35 kg/m2,
and who were inadequately controlled
(HbA1c C7.0% to B10.0%) by diet and
vildagliptin 50 mg bid monotherapy. The key
exclusion criteria were: FPG C15.0 mmol/L;
history of type 1 diabetes, acute metabolic
conditions such as ketoacidosis, lactic acidosis;
patients with congestive heart failure (New York
Heart Association Class III or IV); myocardial
infarction, or coronary artery bypass surgery in
the past 6 months, unstable angina in the past
Screening Run-in period Double-blind treatment period
Vildagliptin 50 mg bid Vildagliptin 50 mg/metformin 250 mg bid





101 102 103** 2 3‡ 4 6
-12 -8 -2 BL† 2 6 14
5
10
Vildagliptin 50 mg/metformin 500 mg bid
*Patients who met all criteria and on stable dose of vildagliptin 50 mg bid for at least 10 weeks proceeded directly to visit 2
(randomization). Patients at visit 1 who met all the criteria but were taking antidiabetic drugs other than vildagliptin entered the
12-week run-in period and proceeded to visit 101. **Eligibility assessment for patients who entered the run -in period. 
†Baseline, the day of randomization. ‡Up titration of patients randomized to vildagliptin/metformin 50/500 mg bid from
vildagliptin/metformin 50/250 mg bid. Bid, twice daily
Fig. 1 Study design
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3 months; acute or chronic liver disease; or
impaired renal function.
Study Endpoints and Assessments
Change in HbA1c from baseline to study end in
all vilda/met groups was the primary efficacy
endpoint. The secondary endpoints included:
HbA1c change from baseline to study end in the
subgroups of patients by metformin dose,
percentage of patients achieving HbA1c target
(\7.0%)/reduction of C0.5% and change in FPG
from baseline to study end. HbA1c values are
reported in National Glycohemoglobin
Standardization Program units (NGSP, %).
Safety assessments included collecting all
adverse events (AEs), serious AEs (SAEs) data
with their severity and suspected relationship to
the study drug, regular assessments of
hematology, biochemistry, vital signs and
body weight. All the laboratory assessments
were performed at a central laboratory
(Mitsubishi Chemical Medience Corporation,
Tokyo, Japan). Patients were asked to record
hypoglycemic events in a study diary.
Hypoglycemia was defined as symptoms
suggestive of hypoglycemia, further confirmed
by self-monitored blood glucose measurement
of \3.1 mmol/L. The event was considered
severe if the patient required assistance of
another person or hospitalization.
Statistical Analysis
Assuming a dropout rate of 5%, 171 patients
were to be randomized in a ratio of 2:1 (vilda/
met 114; vilda/placebo: 57) to achieve the target
sample size of 162. This sample size would
ensure 90% power to detect a between-group
difference of 0.6 absolute units in HbA1c at a
one-sided significance level of 0.025 and a
standard deviation of 1.1%. The sample size of
57 patients in each vilda/met subgroup would
ensure 90% power with a one-sided significance
level of 0.025 to detect a reduction of 0.5
absolute units in HbA1c from baseline at a
standard deviation of 1.0%. Statistical analysis
was performed using SAS 9.2 (SAS Institute Inc.,
Cary NC, USA).
All randomized patients who received at
least one dose of the study drug and had at
least one post-randomization efficacy parameter
(HbA1c, FPG) assessment constituted the full
analysis set (FAS). The primary and secondary
efficacy analyses were based on FAS. The
changes in HbA1c and FPG from baseline to
study endpoint [final available assessment value
at any visit up to the final visit (week 14)]
reported as mean ± SE were analyzed using the
analysis of covariance model, with treatment as
a classification variable and baseline value as a
covariate. The last observation carried forward
method was used for imputing missing data.
Chi-squared test was used to assess and
compare the proportion of responders in the
two groups. Safety data were summarized
descriptively by treatment for the safety
analysis set which included all the patients
who received at least one dose of the study drug.
Ethics and Good Clinical Practice
The independent Ethics Committee/
Institutional Review Board at each center
reviewed and approved the study protocol. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study. The study is registered with
ClinicalTrials.gov, identifier: NCT01811485.
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RESULTS
Patient Disposition and Baseline
Characteristics
A total of 171 patients were randomized (vilda/
met, n = 115; vilda/placebo, n = 56) of which 160
(93.6%) patients completed the study. The most
common reasons for discontinuations were AEs
in the vilda/met group (3.5%) and unsatisfactory
therapeutic effectiveness in the vilda/placebo
group (5.4%) (Fig. 2). Patient demographics and
baseline characteristics were comparable between
the two treatment groups (Table 1). The patients
had an overall age (mean ± SD) 57.0 ± 10.5 years,
BMI 25.8 ± 3.4 kg/m2, FPG 8.8 ± 1.8 mmol/L and
T2DM duration 7.0 ± 6.6 years. Baseline HbA1c
was similar between the two groups (Table 1).
Almost 80% of the patients received concomitant
medications at baseline. The most frequently used
concomitant medications were lipid-lowering
drugs (42.1%) and antihypertensives (39.8%).
Efficacy
The mean HbA1c change over 14 weeks is
shown in Fig. 3a. After 2 weeks, the mean
HbA1c levels were lower in all vilda/met
groups compared with the vilda/placebo
group. At week 14, a statistically significant
between-treatment difference in (mean ± SE)
HbA1c of -1.0 ± 0.1% (P\0.001), in favor of
the vilda/met group was observed (both doses
combined) (Table 2). Statistically significant
Fig. 2 Flow diagram depicting patient disposition
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reductions (P\0.001) in HbA1c from baseline
were also observed for the vilda/met 50/250 mg
bid and vilda/met 50/500 mg bid subgroups
(Fig. 3b). The placebo-corrected difference for
the change in HbA1c was -0.8% [95%
confidence interval (CI) -1.0%, -0.6%] and
-1.2% (95% CI -1.4%, -1.0%) in the vilda/met
50/250 and 50/500 mg subgroups, respectively.
The proportion of patients who achieved
either an HbA1c of \7.0% or an HbA1c drop of
C0.5% at week 14 was significantly higher
(P\0.001) for the vilda/met group compared
with the vilda/placebo group (Table 3). 32.1%
and 59.3% of patients in the vilda/met
50/250 mg and vilda/met 50/500 mg
subgroups, respectively, achieved
HbA1c\7.0%. Absolute mean changes in
HbA1c from baseline to endpoint were greater
in the vilda/met group for the various
subgroups of patients defined by age, gender,
baseline BMI, baseline HbA1c and baseline FPG.
In the vilda/met group, mean reductions in
HbA1c were numerically higher for patients
with higher baseline HbA1c values.









Age (years) 57.5 ± 10.9 56.2 ± 9.8 57.0 ± 10.5
C65 years [n (%)] 35 (30.4) 11 (19.6) 46 (26.9)
Men [n (%)] 82 (71.3) 40 (71.4) 122 (71.3)
Body weight (kg) 69.6 ± 12.5 72.0 ± 11.3 70.4 ± 12.1
BMI (kg/m2) 25.5 ± 3.4 26.5 ± 3.3 25.8 ± 3.4
HbA1c (%) 7.9 ± 0.8 8.0 ± 0.8 7.9 ± 0.8
B8% [n (%)] 77 (67.0) 37 (66.1) 114 (66.7)
[8 to B9% [n (%)] 23 (20.0) 11 (19.6) 34 (19.9)
[9% [n (%)] 15 (13.0) 8 (14.3) 23 (13.5)
FPG (mmol/L) 8.8 ± 1.7 8.9 ± 2.0 8.8 ± 1.8
C8.9 mmol/L [n (%)] 49 (42.6) 23 (41.1) 72 (42.1)
Duration of T2DM (years) 7.0 ± 6.5 7.1 ± 6.9 7.0 ± 6.6
eGFR (MDRD) [mL/min/1.73 m2, n (%)]
Normal[80 106 (92.2) 53 (94.6) 159 (93.0)
Mild C50 to B80 9 (7.8) 3 (5.4) 12 (7.0)
Data are expressed as mean ± standard deviation, unless speciﬁed otherwise
BMI body mass index, eGFR estimated glomerular ﬁltration rate, FPG fasting plasma glucose, HbA1c glycosylated
hemoglobin, MDRD modiﬁcation of diet in renal disease, SPC single-pill combination, T2DM type 2 diabetes mellitus
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The mean FPG over 14 weeks is shown in
Fig. 4. The mean change in FPG from baseline to
endpoint was greater for patients receiving
vilda/met (-0.7 ± 0.2 mmol/L) compared with
those receiving vilda/placebo (0.9 ± 0.2 mmol/
L), with a statistically significant between-
treatment difference of -1.6 ± 0.3 mmol/L
(P\0.001). The placebo-corrected reductions
in FPG from baseline to endpoint were
-1.5 ± 0.3 (95% CI -2.1, -0.8) and -1.8 ± 0.3
(95% CI -2.4, -1.2) mmol/L in the vilda/met
50/250 mg and 50/500 mg subgroups,
respectively.
Safety
The overall safety profile is summarized in
Table 4. The incidence of AEs was lower in the
vilda/met group (43.5%) compared with the
vilda/placebo group (67.9%). The incidences of
AEs were similar between the two vilda/met
subgroups (44.6% and 42.4% for vilda/met
50/250 and 50/500, respectively). Most of the
AEs were mild or moderate in severity. The most
frequently reported AEs by system organ class
(SOC) were ‘infections and infestations’ (16.5%
vs. 25.0%) and gastrointestinal disorders (16.5%
vs. 14.3%) in the vilda/met and vilda/placebo
groups, respectively. Nasopharyngitis was the
most frequently reported AE in both the groups
(9.6% for vilda/met vs. 17.9% for
vilda/placebo). Discontinuations due to AEs
were low in both the groups (3.5% and 3.6%
in the vilda/met and vilda/placebo groups,
respectively).
Three patients reported SAEs: syncope and
convulsion in one patient in the vilda/met
50/500 mg subgroup; epiglottitis and gastric
cancer in one patient each in the
vilda/placebo group. There were no deaths in
the study. There were no hypoglycemic events
reported in either group. Asymptomatic mild
elevations in pancreatic enzymes were reported
in six patients. However, none of the events
were considered as AEs of acute pancreatitis by
the investigator and all patients completed the
study. Body weight remained constant in both
the groups after 14 weeks of treatment:
?0.1 ± 0.1 kg (baseline, 69.5 ± 12.6 kg) in the
vilda/met group and ?0.2 ± 0.2 kg
(72.1 ± 11.3 kg) in the vilda/placebo group.
Fig. 3 a Mean glycosylated hemoglobin (HbA1c %) by
treatment and visit (full analysis set). b Adjusted mean
change in HbA1c from baseline to endpoint (full analysis
set). *P\0.001. BL baseline, EP endpoint, SE standard
error, SPC single-pill combination
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DISCUSSION
This is the first randomized clinical study of an
SPC of DPP-4 inhibitor and metformin in
Japanese patients with T2DM. The goal of the
study was to assess the efficacy and safety of
vildagliptin/metformin SPC over 14 weeks in
Japanese patients with T2DM inadequately
controlled by diet, exercise, and vildagliptin
monotherapy.
The present study showed that vildagliptin/
metformin SPC is efficacious, safe and well-
tolerated in Japanese patients with T2DM. The
HbA1c reduction observed with the SPC
(-0.8%; baseline: 7.9%) in patients
inadequately controlled by vildagliptin
monotherapy was similar to the earlier
reported drop in HbA1c with free-dose
combination of vildagliptin/metformin in
patients inadequately controlled by metformin
monotherapy [10]. Almost half of patients
treated with vilda/met SPC achieved the JDS
recommended glycemic target of HbA1c\7.0%
[5] with three-fourths of patients demonstrating
a clinically relevant drop in HbA1c (C0.5%)
[12], thus, highlighting the benefit of switching
patients who are inadequately controlled with
vildagliptin monotherapy to the vildagliptin/
metformin SPC. The mean reduction in FPG
levels was also significantly higher for the vilda/
met group compared with the vilda/placebo
group, which is consistent with the mechanism
of action of metformin to decrease the
overnight hepatic glucose production [13]. The
data presented here are the first data to establish
the clinical efficacy of metformin 250 mg bid in
Japanese patients, as such closing an important
gap. Even this low metformin dose resulted in
Table 2 ANCOVA results for change in HbA1c (%) from baseline to endpoint (full analysis set)








95% CI P value
Vildagliptin/metformin SPC (both
doses combined)
115 7.9 (0.1) -0.8 (0.1) -1.0 (0.1) -1.2, -0.8 \0.001
Vildagliptin/placebo SPC 56 8.0 (0.1) 0.1 (0.1)
ANCOVA analysis of covariance, CI conﬁdence interval, HbA1c glycosylated hemoglobin, SE standard error,
SPC single-pill combination







HbA1c\7.0% [n/N** (%)] 49/107 (45.8)* 7/52 (13.5)
Reduction of HbA1c C0.5% [n/N (%)] 85/115 (73.9)* 9/56 (16.1)
HbA1c glycosylated hemoglobin, SPC single-pill combination
* P\0.001
** Denominator includes patients with baseline HbA1c C7.0% and endpoint HbA1c measurement
 Denominator includes patients with both baseline and endpoint HbA1c measurements
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clinically relevant glycemic benefit with an
HbA1c difference of 0.8% vs. vilda/placebo
group.
The overall incidence of AEs was lower in the
vilda/met group compared with the
vilda/placebo group. This can be mostly
attributed to a higher incidence of mild events
of nasopharyngitis, all of which were
considered unrelated to the study drug. This is
likely a chance finding, given that the only
treatment change in this patient was adding
placebo treatment to already existing
vildagliptin treatment. There were no
hypoglycemic events reported in this study,
despite the significant improvement in the
glycemic control with the SPC, which is
consistent with the earlier known safety
profile of vildagliptin in Japanese patients with
T2DM [14, 15] and a potential vildagliptin
mediated protective effect against
hypoglycemia through enhanced gastric
inhibitory polypeptide [9]. There was no
weight gain over 14 weeks of treatment in
both the groups reconfirming the previously
established weight neutrality effect of
metformin [16]. Overall, the safety and
tolerability of the vilda/met group were in line
with the known safety profile of vildagliptin as a
single agent or as a free combination with
metformin [10, 14, 15].
Treatment with SPC of vildagliptin/
metformin targets the multiple
pathophysiological abnormalities of T2DM
such as impaired insulin secretion, increased
endogenous glucose production, and decreased
utilization of glucose, in turn helping patients















Adverse events (AEs) 50 (43.5) 25 (44.6) 25 (42.4) 38 (67.9)
AEs related to the study drug 20 (17.4) 10 (17.9) 10 (16.9) 12 (21.4)
Serious AEs 1 (0.9) 0 (0.0) 1 (1.7) 2 (3.6)
Discontinuation due to AEs 4 (3.5) 1 (1.8) 3 (5.1) 2 (3.6)
Hypoglycemia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Deaths 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AEs adverse events, SPC single-pill combination
Fig. 4 Mean fasting plasma glucose (mmol/L) by treat-
ment and visit (full analysis set). BL baseline, EP endpoint,
SPC single-pill combination
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to maintain good glycemic control. Metformin
complements the mechanism of action of
vildagliptin by raising absolute levels of
glucagon like peptide-1 (GLP-1) [9].
Furthermore, SPC formulations have
advantages such as reduced pill burden,
improved convenience and adherence over
free-dose combinations [17]. Results from a
meta-analysis showed that SPC reduces the
risk of non-compliance by 26% compared with
the free-dose combination [11].
CONCLUSION
In conclusion, robust glucose-lowering efficacy
along with good safety and tolerability makes
the vildagliptin/metformin SPC an attractive
treatment option for Japanese patients with
T2DM who require additional treatment
beyond vildagliptin monotherapy.
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